YLX
Buspirone
Created: | 2023-02-09 |
Last modified: | 2024-05-15 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 59 |
Chiral Atom Count | 0 |
Bond Count | 62 |
Aromatic Bond Count | 6 |
Chemical Component Summary | |
---|---|
Name | Buspirone |
Systematic Name (OpenEye OEToolkits) | 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione |
Formula | C21 H31 N5 O2 |
Molecular Weight | 385.503 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 |
SMILES | CACTVS | 3.385 | O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)c4ncccn4 |
SMILES | OpenEye OEToolkits | 2.0.7 | c1cnc(nc1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O |
Canonical SMILES | CACTVS | 3.385 | O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)c4ncccn4 |
Canonical SMILES | OpenEye OEToolkits | 2.0.7 | c1cnc(nc1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O |
InChI | InChI | 1.06 | InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2 |
InChIKey | InChI | 1.06 | QWCRAEMEVRGPNT-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB00490 |
---|---|
Name | Buspirone |
Groups |
|
Description | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs.[L4478] Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'.[A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA [A181751] and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety. It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate.[L7375] The potential use of buspirone in combination with [melatonin] in depression and cognitive impairment via promoting neurogenesis has also been investigated.[A181751] |
Synonyms |
|
Brand Names |
|
Indication | Indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.[L4478] |
Categories |
|
ATC-Code | N05BE01 |
CAS number | 36505-84-7 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
5-hydroxytryptamine receptor 1A | MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCA... | unknown | partial agonist |
D(2) dopamine receptor | MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF... | unknown | antagonist |
D(3) dopamine receptor | MASLSQLSGHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV... | unknown | antagonist |
D(4) dopamine receptor | MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLA... | unknown | antagonist |
Alpha-1 adrenergic receptors | MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILS... | unknown | partial agonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL49 |
PubChem | 2477 |
ChEMBL | CHEMBL49 |
ChEBI | CHEBI:3223 |
CCDC/CSD | MEQCOB |
COD | 2211445 |